Trastuzumab - an overview

trastuzumab  In the DESTINY-Breast04 trial, trastuzumab deruxtecan showed superior activity over standard chemotherapy options in patients with HER2-low advanced breast In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed

Trastuzumab was developed by Genentech Inc as a recombinant humanized monoclonal antibody directed against the Trastuzumab deruxtecan provides durable benefits to patients with heavily pretreated HER2

trastuzumab ให้ครั้งแรก 4mgkg และให้ต่อ 2mgkg ทุกสัปดาห์จนกระทั่งมี disease progression หรือมี unacceptable toxicity ยา capecitabineในมะเร็งเต้านมระยะที่ 4 สรุปคำแนะนำ ควร Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor The majority of patients with metastatic breast